NCT01313559View on ClinicalTrials.gov

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 15, 2012

Study Completion Date

November 29, 2012

Conditions
Castrate Resistant Prostate CancerChemotherapy Naive Prostate CancerProstate Cancer
Interventions
DRUG

Pasireotide

Given IM

DRUG

Everolimus

Given PO

OTHER

Laboratory biomarker analysis

Correlative studies

Trial Locations (2)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

06520

Yale Cancer Center, New Haven

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER